Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025)
Roivant Sciences (ROIV) reported Income from Non-Controlling Interests of -$47.8 million for Q4 2025, up 6.81% on a YoY basis from -$44.8 million in Q4 2024, and up 8.97% quarter-over-quarter from -$52.5 million in Q3 2025.
Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Roivant Sciences has reported Income from Non-Controlling Interests for 6 years, with the latest figure at -$47.8 million in Q4 2025.
- For the quarter ending Q4 2025, Income from Non-Controlling Interests rose 6.81% year-over-year to -$47.8 million; the trailing twelve-month figure through Dec 2025 stood at -$202.2 million (down 24.52% YoY), and the FY2026 full-year result was -$98.1 million, up 46.88% from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at -$47.8 million, up from -$52.5 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$17.2 million in Q3 2021, with the low at -$52.5 million in Q3 2025.
- Historically, Income from Non-Controlling Interests has averaged -$34.2 million across 5 years, with a median of -$32.9 million in 2022.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests sank 299.13% — and 2023, when it rose 28.47%.
- Roivant Sciences' Income from Non-Controlling Interests stood at -$21.5 million in 2021, then tumbled by 52.59% to -$32.9 million in 2022, then climbed by 28.47% to -$23.5 million in 2023, then slumped by 118.15% to -$51.3 million in 2024, then climbed by 6.81% to -$47.8 million in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$47.8 million (Q4 2025), -$52.5 million (Q3 2025), and -$50.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.81 Mn |
| Sep 30, 2025 | -52.52 Mn |
| Jun 30, 2025 | -50.56 Mn |
| Dec 31, 2024 | -51.31 Mn |
| Sep 30, 2024 | -49.74 Mn |
| Jun 30, 2024 | -37.81 Mn |
| Dec 31, 2023 | -23.52 Mn |
| Sep 30, 2023 | -26.79 Mn |
| Jun 30, 2023 | -36.03 Mn |
| Dec 31, 2022 | -32.88 Mn |
| Sep 30, 2022 | -24.33 Mn |
| Jun 30, 2022 | -21.98 Mn |
| Dec 31, 2021 | -21.55 Mn |
| Sep 30, 2021 | -17.16 Mn |
| Jun 30, 2021 | -18.90 Mn |
| Dec 31, 2020 | -14.57 Mn |
| Sep 30, 2020 | -18.10 Mn |
| Jun 30, 2020 | -4.73 Mn |